SUMMARY**chlorure de lutétium (^{177}Lu)****LUNCA 40 GBq/mL****radiopharmaceutical precursor, solution****First listing****Original French opinion adopted by the Transparency Committee on
15 May 2024****The legally binding text is the original French opinion version****Summary of opinion**

Favourable opinion for reimbursement in the MA indication: “LUNCA is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (^{177}Lu) chloride.”

Transparency Committee's conclusions**Clinical Benefit**

Considering the fact that LUNCA (lutetium (^{177}Lu) chloride) is a radiopharmaceutical precursor that cannot be assessed without combination with a carrier molecule that has been specifically developed to treat a disease by radionuclide therapy.

→ Public health benefit

Non-assessable without combination with a carrier molecule.

Considering all these elements, the Committee deems that the clinical benefit of LUNCA (lutetium (^{177}Lu) chloride) radiopharmaceutical precursor, solution cannot be assessed.

The Committee issues a favourable opinion for inclusion of LUNCA (lutetium (^{177}Lu) chloride) radiopharmaceutical precursor, solution in the list of covered drugs for inpatients approved for use in the indication and at the MA dosages.

Clinical Added Value

Considering the fact that LUNCA (lutetium (^{177}Lu) chloride) is a radiopharmaceutical precursor that cannot be assessed without combination with a carrier molecule that has been specifically developed to treat a disease by radionuclide therapy,

the Committee deems that the clinical added value of LUNCA (lutetium (^{177}Lu) chloride) radiopharmaceutical precursor, solution cannot be assessed.